Pharmacological properties
The drug Psoricap exhibits high antibacterial activity against a number of pathogenic microorganisms, such as streptococci, staphylococci, Pseudomonas aeruginosa and Escherichia coli, Proteus. The antifungal activity of the drug is especially pronounced against Pytyrosporum ovale and Pytyrosporum orbiculare, which cause inflammation and excessive peeling in psoriasis and other skin diseases. Psoricap is active against microorganisms that are located both on the surface and in the deep layers of the epidermis.
The special composition of the cream exhibits hydrating properties, increases the antibacterial and antifungal effects of zinc pyrithione, helps eliminate burning and itching. Activated zinc pyrithione contained in the cream inhibits the pathological growth of cells of the surface layers of the skin, which are in a state of pathological hyperproliferation, eliminates excessive peeling in psoriasis and other skin diseases. The drug acts against microorganisms located both on the surface and in the deep layers of the epidermis.
When applied externally, zinc pyrithione is deposited in the superficial (epidermal) layers of the skin. Systemic absorption is slow. It is found in the blood in small amounts.
Indication
Psoriasis, atopic dermatitis, seborrheic eczema in adults and children over 1 year of age, especially in severe forms, as well as with itching, irritation, inflammation and increased dryness of the skin.
Application
Lubricate the affected areas of the skin 2 times a day. For psoriasis, the course of treatment is 1-1.5 months, for atopic dermatitis – 3-4 weeks, for other diseases, the cream is prescribed until the symptoms disappear completely. For residual symptoms (hyperemia, dryness, peeling, pigmentation), the cream is continued to be used for 1-2 weeks.
Contraindication
Hypersensitivity to one of the components of the drug.
Side effects
In individuals with individual intolerance, hypersensitivity reactions are extremely rare, including skin rashes, redness, itching, burning, and changes at the site of application.
Special instructions
Do not allow the cream to get into the eyes. If the frequency of application of the cream is increased, a slight short-term local burning of the skin may occur.
The drug can be used during remission for maintenance therapy and relapse prevention, which allows you to quickly eliminate the manifest phase and accelerate clinical recovery. During remission, the cream is applied to the skin areas at the first signs of exacerbation of the disease.
Use during pregnancy and breastfeeding. During pregnancy and breastfeeding, the drug is used only if the benefit of use outweighs the potential risk to the fetus/child. The cream should not be applied to the nipples during breastfeeding.
Children: Do not use in children under 1 year of age.
The ability to influence the reaction speed when driving vehicles or working with other mechanisms. Does not affect.
Interactions
The drug is not recommended for use with ointments or creams containing corticosteroids.
Overdose
Not described.
Storage conditions
In the original packaging at a temperature not exceeding 25 °C. Do not freeze.
